

## This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Assays &amp; screens</b>			
Induced pluripotent stem (iPS) cells for production of human platelets	<p><i>In vitro</i> and mouse studies suggest that controlling <i>c-Myc</i> expression in iPS cells could help optimize the production of platelets for transfusions. In cultured iPS cells, the highest platelet yield occurred when researchers initially raised <i>c-Myc</i> expression and then lowered it when expression reached a peak. In mice, iPS cell-derived platelets coordinated with native platelets to form a thrombus in injured vessel walls following laser injury, showing that the iPS cell-derived platelets retained function. Next steps include developing megakaryocyte progenitor cells from the culture system to increase the efficiency of platelet generation.</p>	Patent application filed covering stem cells and hematopoiesis; unavailable for licensing	<p>Takayama, N. <i>et al. J. Exp. Med.</i>; published online Nov. 22, 2010; doi:10.1084/jem.20100844</p> <p><b>Contact:</b> Koji Eto, The University of Tokyo, Tokyo, Japan e-mail: <a href="mailto:keto@ims.u-tokyo.ac.jp">keto@ims.u-tokyo.ac.jp</a></p>
	<p><b>SciBX 3(48); doi:10.1038/scibx.2010.1458</b> Published online Dec. 16, 2010</p>		